{"id":29496,"date":"2016-02-01T12:17:30","date_gmt":"2016-02-01T12:17:30","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=29496"},"modified":"2016-02-05T11:56:30","modified_gmt":"2016-02-05T11:56:30","slug":"bms-sells-pipeline-compounds-to-viiv-healthcare","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/29496","title":{"rendered":"BMS sells pipeline compounds to ViiV Healthcare"},"content":{"rendered":"

Simon Collins, HIV i-Base<\/strong><\/p>\n

On 18 December 2015, Bristol-Myers Squibb (BMS) announced that the company was selling its discovery, preclinical and clinical programmes for its HIV pipeline to ViiV Healthcare.<\/strong> [1]<\/p>\n

The clinical pipeline includes an attachment inhibitor (BMS-663068), currently in phase III studies and a maturation inhibitor (BMS-955176), currently in phase IIb development.<\/p>\n

Both compounds are especially important for people with drug resistance to existing HIV drugs.<\/p>\n

Details of the “active” preclinical and discovery stage programmes were not included in the statement.<\/p>\n

ViiV will pay $350 million up front, with potential regulatory and milestone payments of up to $518 million for the clinical assets and up to $587 million for the discovery and pre-clinical programmes. ViiV will also pay sales-based payments for any compounds that become licensed.<\/p>\n

If cleared by US anti-trust laws, the divestment should be completed by mid-2016. BMS announced in June 2015 that the company was withdrawing from virology research. [2]<\/p>\n

BMS drugs that are already licensed (efavirenz, Atripla, atazanavir and atazanavir\/cobicistat) are not affected by the agreement.<\/p>\n

References:<\/p>\n

    \n
  1. BMS Press Release. Bristol-Myers Squibb to sell its HIV R&D portfolio to ViiV Healthcare, (18 December 2015).
    \nhttp:\/\/news.bms.com\/press-release\/partnering-news\/bristol-myers-squibb-sell-its-hiv-rd-portfolio-viiv-healthcare<\/a><\/li>\n
  2. BMS Press Release. Bristol-Myers Squibb Expands R&D Presence Within Hubs of World Class Science and Innovation (25 June 2015).
    \n    http:\/\/news.bms.com\/press-release\/rd-news\/bristol-myers-squibb-expands-rd-presence-within-hubs-world-class-science-and-i<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base On 18 December 2015, Bristol-Myers Squibb (BMS) announced that the company was selling its discovery, preclinical and clinical programmes for its HIV pipeline to ViiV Healthcare. [1] The clinical pipeline includes an attachment inhibitor (BMS-663068), currently …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-29496","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/29496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=29496"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/29496\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=29496"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=29496"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=29496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}